Karen Jones, MD
Obstetrics & Gynecology · Newport, ARNPI 1952371056
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $253 of the $353 with a category attached, or 71.6%. 8 manufacturers reported payments, led by Astellas Pharma US Inc at 32.1% of the total. Reporting peaked in 2023 at $135 and has fallen 66.4% since, to $46 in 2025. That places this record below the midpoint for obstetrics & gynecology clinicians in AR, where the typical reported total is $1,340.
Across 16 payments — averaging $22.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$113
- AbbVie$113
- Pfizer$30
- Organogenesis Inc.$29
- Pacira Pharmaceuticals Incorporated$22
- Avion Pharmaceuticals$17
- plus $29 from 2 others
What the payments were for
- Food & beverage$25372%
- Education$10028%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 2 | $113 |
| AbbVie | 8 | $113 |
| Pfizer | 1 | $30 |
| Organogenesis Inc. | 1 | $29 |
| Pacira Pharmaceuticals Incorporated | 1 | $22 |
| Avion Pharmaceuticals | 1 | $17 |
| Millicent US Inc | 1 | $17 |
| Merck | 1 | $12 |
How this compares
$353 in reported general payments places this provider in the 25th percentile of 272 obstetrics & gynecology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $5,825 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Newport
- Michael CopeLittle Rock$147K
- Jeanmarie HouseholderFort Smith$140K
- Timothy BellFort Smith$53K
- Paige PartridgeJohnson$50K
- David ShenkerLittle Rock$28K
- Christopher TaylorHarrison$24K
- Julia GoodwinLittle Rock$16K
- Lisa WatermanSpringdale$16K
- Erin LargeFayetteville$16K
- Christopher HallRogers$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.